No gain from adding cetuximab to FOLFOX4 in patients with resected stage III colon cancer

Final results of the PETACC8 Intergroup phase III trial showed that adding cetuximab to FOLFOX4 does not improve overall survival in patients with resected stage III colon cancer whose tumors express KRAS-wild type (-wt) and KRAS/BRAF-wt, but a certain benefit is observed in several subgroups of patients. The study results are reported by Dr Julien Taieb on behalf of the PETACC researchers at the Presidential Symposium of the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Read more here.